Chrysin (Synonyms: 白楊素; 5,7-Dihydroxyflavone)

目錄號: HY-14589 純度: 99.85%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計算器

Chrysin 是一種雌激素阻斷劑。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Chrysin Chemical Structure

CAS No. : 480-40-0

1. 客戶無需承擔(dān)相應(yīng)的運輸費用。

2. 同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥500	In-stock
5 g		詢價
10 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Chrysin:

Chrysin (Standard) 詢價

MCE 顧客使用本產(chǎn)品發(fā)表的 7 篇科研文獻(xiàn)

•Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
•Cell Prolif. 2024 Sep 27:e13732. [Abstract]
•Mol Neurobiol. 2024 Oct 21. [Abstract]
•Regen Ther. 13 January 2022.
•Cell Cycle. 2022 Jan 5;1-13. [Abstract]
•Clin Sci. 2021 Jul 20;CS20210571. [Abstract]
•Int J Mol Med. July 13, 2021.

Chrysin 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 Estrogen Receptor/ERR 亞型特異性產(chǎn)品:

查看所有亞型

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

生物活性
實驗參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Chrysin is one of the most well known estrogen blockers.

IC₅₀ & Target

estrogen

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
2008	IC₅₀	28.62 μM Compound: 2, Chry	Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-375	IC₅₀	29.65 μM Compound: 8	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 19782567]
A-375	IC₅₀	33.23 μM Compound: 2, Chry	Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-431	IC₅₀	29.39 μM Compound: 2, Chry	Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-431	IC₅₀	60.13 μM Compound: 2, Chry	Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A549	IC₅₀	> 1 x 10^-4 M Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by XTT assay Cytotoxicity against human A549 cells after 72 hrs by XTT assay	[PMID: 20619940]
A549	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
A549	IC₅₀	> 50 μM Compound: Chrysin	Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
A549	IC₅₀	19.88 μM Compound: 8	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19782567]
A549	EC₅₀	233 μM Compound: 3	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 12027739]
A549	IC₅₀	28 μM Compound: Chrysin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
A549	IC₅₀	47.8 μM Compound: Chrysin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30031652]
B16-BL6	EC₅₀	74.4 μM Compound: 3	Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 12027739]
B16-F10	IC₅₀	17.45 μM Compound: Chrysin	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 30031652]
BALB/3T3	IC₅₀	248.2 μM Compound: 2	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
BXPC-3	IC₅₀	54.27 μM Compound: 2, Chry	Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
C13	IC₅₀	49.66 μM Compound: 2, Chry	Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
C8166	CC₅₀	110 μg/mL Compound: 5	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	13.4 μg/mL Compound: 5	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
Caco-2	IC₅₀	9.5 μM Compound: 23	Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay	[PMID: 28793973]
DLD-1	IC₅₀	18.62 μM Compound: 4	Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
DU-145	IC₅₀	9.81 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) DU145 cells by MTT assay Cytotoxicity against Homo sapiens (human) DU145 cells by MTT assay	10.1007/s00044-010-9395-1
H22	IC₅₀	1671 μM Compound: 1, Chrysin	Cytotoxicity against mouse H22 cells assessed as growth inhibition by MTT assay Cytotoxicity against mouse H22 cells assessed as growth inhibition by MTT assay	[PMID: 24556144]
H9	IC₅₀	47 μM Compound: 11	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9	EC₅₀	5 μM Compound: 11	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
HCT-116	IC₅₀	> 100 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay	10.1007/s00044-010-9395-1
HCT-15	IC₅₀	54.43 μM Compound: 2, Chry	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
HEK293	IC₅₀	77.45 μM Compound: 2, Chry	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
HEK-293T	IC₅₀	319.36 μM Compound: Chrysin	Cytotoxicity against human 293T cells after 48 hrs by MTT assay Cytotoxicity against human 293T cells after 48 hrs by MTT assay	[PMID: 30031652]
HeLa	IC₅₀	≥ 10 μM Compound: chrysin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19278239]
HeLa	EC₅₀	111 μM Compound: 3	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 12027739]
HeLa	IC₅₀	14.2 μM Compound: Chrysin	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	[PMID: 28797675]
HeLa	IC₅₀	2.9 x 10^-5 M Compound: 1	Cytotoxicity against human HeLa cells after 72 hrs by XTT assay Cytotoxicity against human HeLa cells after 72 hrs by XTT assay	[PMID: 20619940]
HeLa	IC₅₀	25.05 μM Compound: Chrysin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30031652]
HeLa	IC₅₀	43 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay	10.1007/s00044-010-9395-1
HepG2	IC₅₀	> 100 μM Compound: Chrysin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26896708]
HepG2	IC₅₀	16.5 μM Compound: 4	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HL-60	IC₅₀	33.98 μM Compound: 8	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19782567]
HT-1080	EC₅₀	94.9 μM Compound: 3	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 12027739]
HT-29	IC₅₀	> 1 x 10^-4 M Compound: 1	Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay	[PMID: 20619940]
HT-29	IC₅₀	19.49 μM Compound: 4	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
Huh-7	CC₅₀	> 50 μM Compound: 18	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Jurkat	IC₅₀	4.9 μM Compound: Chrysin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	6.1 μM Compound: Chrysin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
K562	IC₅₀	> 100 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) K562 cells by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells by MTT assay	10.1007/s00044-010-9395-1
K562	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
K562	IC₅₀	> 50 μM Compound: Chrysin	Antiproliferative activity against human K562 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
KB	IC₅₀	29.6 μM Compound: Chrysin	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
KYSE-510	IC₅₀	63 μM Compound: Chrysin	Cytotoxicity in human KYSE-510 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay Cytotoxicity in human KYSE-510 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	[PMID: 28797675]
L02	IC₅₀	> 100 μM Compound: Chrysin	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 26896708]
MCF7	IC₅₀	2.6 μM Compound: 10	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MCF7	IC₅₀	25.66 μM Compound: Chrysin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30031652]
MCF7	IC₅₀	26.9 μM Compound: Chrysin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
MCF7	IC₅₀	50 nM Compound: Chrysin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	50.32 μM Compound: 2, Chry	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
MCF7	GI₅₀	69 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay	10.1007/s00044-012-0423-1
MDA-MB-231	IC₅₀	33 μM Compound: Chrysin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
MDCK	IC₅₀	1.5 μM Compound: 10	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
Mesenchymal stem cells	EC₅₀	77.7 μM Compound: 1	Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay	[PMID: 37077388]
MOLT-4	GI₅₀	58.6 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay	10.1007/s00044-012-0423-1
Monocyte	IC₅₀	2.4 μM Compound: chrysin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
MRC5	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
MRC5	IC₅₀	> 100 μM Compound: Chrysin	Cytotoxicity against human MRC5 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
NCI/ADR-RES	IC₅₀	51.04 μM Compound: 2, Chry	Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
NCI-H1299	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
NCI-H1299	IC₅₀	> 50 μM Compound: Chrysin	Antiproliferative activity against human H1299 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human H1299 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
Neutrophil	IC₅₀	53 μM Compound: 4a	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	9.59 μM Compound: 4a	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
PC-3	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
PC-3	IC₅₀	> 50 μM Compound: Chrysin	Antiproliferative activity against human PC3 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
RBL-2H3	IC₅₀	> 500 μM Compound: 11	Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge	[PMID: 14510616]
RD	EC₅₀	15.89 μM Compound: CR	Antiviral activity against EV71 infected in human RD cells assessed as protection against virus infection after 72 hrs by MTS assay Antiviral activity against EV71 infected in human RD cells assessed as protection against virus infection after 72 hrs by MTS assay	[PMID: 27776325]
SGC-7901	IC₅₀	> 100 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay	10.1007/s00044-010-9395-1
SW480	IC₅₀	31.08 μM Compound: 4	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
T-cell	CC₅₀	428.27 μM Compound: 1, CR	Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay	[PMID: 21131104]
T-cell	IC₅₀	44.16 μM Compound: 1, CR	Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay	[PMID: 21131104]
THP-1	IC₅₀	23.38 μM Compound: 8	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 19782567]

體外研究
(In Vitro)

Chrysin 主要存在于西番蓮、蜂蜜和蜂膠中，是一種潛在的治療和預(yù)防劑，可抑制多種人類癌細(xì)胞的增殖和侵襲。盡管 Chrysin 在多種癌癥中具有抗癌作用，但對其在卵巢癌中的功能作用知之甚少，而卵巢癌的預(yù)后較差且對傳統(tǒng)治療藥物具有化療耐藥性。Chrysin 通過增加活性氧 (ROS) 產(chǎn)生和細(xì)胞質(zhì) Ca²⁺ 水平以及誘導(dǎo)線粒體膜電位 (MMP) 損失來抑制卵巢癌細(xì)胞增殖并誘導(dǎo)細(xì)胞死亡。在濃度反應(yīng)實驗中，Chrysin 激活 ES2 和 OV90 細(xì)胞中的 MAPK 和 PI3K/AKT 通路。Chrysin 通過調(diào)節(jié)經(jīng)典 Wnt 和核因子 NF-κB 信號通路級聯(lián)癌細(xì)胞來抑制腫瘤生長。與未處理的對照細(xì)胞相比，Chrysin 刺激 ES2 和 OV90 細(xì)胞中 AKT 和 P70S6K 蛋白的磷酸化。此外，Chrysin 還可激活卵巢癌細(xì)胞中 MAPK 通路成員的磷酸化 ERK1/2、p38 和 JNK 蛋白^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

254.24

Formula

C₁₅H₁₀O₄

CAS 號

480-40-0

性狀

固體

顏色

Light yellow to yellow

中文名稱

柯因；5,7-二羥黃酮

結(jié)構(gòu)分類

初始來源

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實驗：

DMSO 中的溶解度 : ≥ 100 mg/mL (393.33 mM; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.9333 mL	19.6665 mL	39.3329 mL
5 mM	0.7867 mL	3.9333 mL	7.8666 mL
10 mM	0.3933 mL	1.9666 mL	3.9333 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.83 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.83 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請依序添加每種溶劑： 50% PEG300 50% Saline
Solubility: 10 mg/mL (39.33 mM); 懸濁液; 超聲助溶

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

請輸入您的動物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購。，Tween 80，均可在 MCE 網(wǎng)站選購。

計算結(jié)果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.85%

選擇批次：

Data Sheet (645 KB) SDS (393 KB)

COA (193 KB) HNMR (267 KB) LCMS (93 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Lim W, et al. Chrysin Attenuates Progression of Ovarian Cancer Cells by Regulating Signaling Cascades and Mitochondrial Dysfunction. J Cell Physiol. 2017 Aug 17. [Content Brief]

Cell Assay ^[1]	The proliferation assays are conducted using a cell proliferation enzyme-linked immunosorbent assay (ELISA) 5-bromo-2'-deoxyuridine (BrdU) kit. Briefly, ES2 and OV90 cells are seeded in a 96-well plate, and then treated with Chrysin (0, 5, 10, 20, 50, and 100 μM) with or without inhibitors (20 μM LY294002, PI3K/AKT; 10 μM U0126, ERK1/2; 10 μM SP600125, JNK; and 20 μM SB203580, p38) in a final volume of 100 μL/well. Aftera48-h incubation, 10 μM BrdU is added to the cell culture, followed by an additional 2-h incubation at 37°C. After labeling the cells with BrdU, they are fixed and then incubated with the anti-BrdU-peroxidase (POD) working solution for 90 min. The anti-BrdU-POD binds to the BrdU incorporated into newly synthesized cellular DNA and these immune complexes are detected by analyzing their reaction with the 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The absorbance values of the reaction product are measured at 370 and 492 nm using an ELISA reader^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Lim W, et al. Chrysin Attenuates Progression of Ovarian Cancer Cells by Regulating Signaling Cascades and Mitochondrial Dysfunction. J Cell Physiol. 2017 Aug 17. [Content Brief]

Cell Assay
^[1]

The proliferation assays are conducted using a cell proliferation enzyme-linked immunosorbent assay (ELISA) 5-bromo-2'-deoxyuridine (BrdU) kit. Briefly, ES2 and OV90 cells are seeded in a 96-well plate, and then treated with Chrysin (0, 5, 10, 20, 50, and 100 μM) with or without inhibitors (20 μM LY294002, PI3K/AKT; 10 μM U0126, ERK1/2; 10 μM SP600125, JNK; and 20 μM SB203580, p38) in a final volume of 100 μL/well. Aftera48-h incubation, 10 μM BrdU is added to the cell culture, followed by an additional 2-h incubation at 37°C. After labeling the cells with BrdU, they are fixed and then incubated with the anti-BrdU-peroxidase (POD) working solution for 90 min. The anti-BrdU-POD binds to the BrdU incorporated into newly synthesized cellular DNA and these immune complexes are detected by analyzing their reaction with the 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The absorbance values of the reaction product are measured at 370 and 492 nm using an ELISA reader^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

[1]. Lim W, et al. Chrysin Attenuates Progression of Ovarian Cancer Cells by Regulating Signaling Cascades and Mitochondrial Dysfunction. J Cell Physiol. 2017 Aug 17. [Content Brief]

Chrysin 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.9333 mL	19.6665 mL	39.3329 mL	98.3323 mL
	5 mM	0.7867 mL	3.9333 mL	7.8666 mL	19.6665 mL
	10 mM	0.3933 mL	1.9666 mL	3.9333 mL	9.8332 mL
	15 mM	0.2622 mL	1.3111 mL	2.6222 mL	6.5555 mL
	20 mM	0.1967 mL	0.9833 mL	1.9666 mL	4.9166 mL
	25 mM	0.1573 mL	0.7867 mL	1.5733 mL	3.9333 mL
	30 mM	0.1311 mL	0.6555 mL	1.3111 mL	3.2777 mL
	40 mM	0.0983 mL	0.4917 mL	0.9833 mL	2.4583 mL
	50 mM	0.0787 mL	0.3933 mL	0.7867 mL	1.9666 mL
	60 mM	0.0656 mL	0.3278 mL	0.6555 mL	1.6389 mL
	80 mM	0.0492 mL	0.2458 mL	0.4917 mL	1.2292 mL
	100 mM	0.0393 mL	0.1967 mL	0.3933 mL	0.9833 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Chrysin480-40-05,7-Dihydroxyflavone柯因5,7-二羥黃酮Estrogen Receptor/ERRInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Chrysin (Synonyms: 白楊素; 5,7-Dihydroxyflavone)

Customer Review

Other Forms of Chrysin:

MCE 顧客使用本產(chǎn)品發(fā)表的 7 篇科研文獻(xiàn)

Chrysin 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 Estrogen Receptor/ERR 亞型特異性產(chǎn)品:

生物活性

實驗參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計算器

稀釋計算器

Chrysin 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Chrysin (Synonyms: 白楊素; 5,7-Dihydroxyflavone)

Customer Review

Other Forms of Chrysin:

Chrysin 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 7 篇科研文獻(xiàn)

Chrysin 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 Estrogen Receptor/ERR 亞型特異性產(chǎn)品:

生物活性

實驗參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Chrysin 相關(guān)抗體:

摩爾計算器

稀釋計算器

Chrysin 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z